ASFV-G-∆I177L as an Effective Oral Nasal Vaccine against the Eurasia Strain of Africa Swine Fever

Figure 1. Kinetics of body temperature values in pigs oronasally (A) or intramuscularly (B) inoculated with ASFV-G-ΔI177L before (Days post-infection) and after challenge (Days post-challenge) with ASFV-G. Each curve represents individual data from each of the animals under each of the treatments. Red curves represent a group of mock-inoculated animals used as a control during both challenge experiments.

Figure 2. Viremia titers in pigs either oronasally or intramuscularly inoculated with ASFV-G-ΔI177L before and after challenge with ASFV-G (A,B). Each curve represents individual data from each of the animals under each of the treatments. Red curves represent mock-inoculated animals used as controls during the challenge. The sensitivity of virus detection was ≥1.8 log10 HAD50/mL.

Figure 3. Evolution of mortality in pigs either oronasally or intramuscularly inoculated with ASFV-G-ΔI177L or mock treated and challenged with 102 HAD50 of ASFV-G.

Figure 4. Anti-ASFV antibody titers detected by ELISA in pigs oronasally (ON) or intramuscularly (IM) inoculated with ASFV-G-ΔI177L. Individual serum ASFV-specific antibody titers (indicated by individual symbols) mediated by IgM, total IgG, IgG1 and IgG2 are represented in panels (A), (B), (C) and (D), respectively. Titers are expressed as the log10 of the reciprocal of the highest dilution of sera at least duplicating OD readings of a pool of mock-infected sera.